Yes, Singapore offers accelerated pathways for drug registration, including the Priority Review and the New Drug Application (NDA) routes. These pathways expedite the evaluation process for drugs addressing unmet medical needs or offering significant therapeutic benefits, ensuring faster access to innovative treatments while maintaining rigorous safety and efficacy standards.
